As multiple companies have – with varying degrees of success – sought to develop next-generation drugs for treating overweight and obesity, Metsera has shown that it is feasible to administer its GLP-1 receptor agonist candidate MET-097i monthly rather than weekly. The VC-backed start-up is now planning to expand clinical development of the drug at a time when the market remains open for successors to the two marketed drugs in the class.
The New York-based company announced 7 January positive topline Phase IIa clinical data for MET-097i at 12 weeks, showing up to 11.3% mean placebo-adjusted weight loss with no plateau observed,...
Key Takeaways
- Metsera announced efficacy data from its Phase IIa study of GLP-1 receptor agonist MET-097i, showing the feasibility of once-monthly dosing.
- The drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?